Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics ABT-199 and ABT-737.

Ning Yu¹, Claire Seedhouse¹, Nigel Russell¹,², Monica Pallis²

¹Department of Haematology, University of Nottingham, Nottingham UK.
²Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, UK

Running title: ABT-199 and ABT-737 in dormant AML

Corresponding author: Dr Claire Seedhouse PhD, Academic Haematology, Clinical Sciences Building, Nottingham University Hospitals City Campus, Nottingham, NG5 1PB, UK. Telephone +44-115-8231822 E-mail: Claire.seedhouse@nottingham.ac.uk

Remaining authors

Dr Ning Yu PhD, Academic Haematology, Clinical Sciences Building, Nottingham University Hospitals City Campus, Nottingham, NG5 1PB, UK. Telephone +44-115-8231823 E-mail: nancieyu@gmail.com

Professor Nigel Russell MD, Centre for Clinical Haematology, Nottingham University Hospitals City Campus, Nottingham, NG5 1PB, UK. Telephone +44-115-9627708 E-mail: Nigel.russell@nottingham.ac.uk

Dr Monica Pallis PhD, Academic Haematology, Clinical Sciences Building, Nottingham University Hospitals City Campus, Nottingham, NG5 1PB, UK. Telephone +44-115-8231823 E-mail: monica.pallis@nottingham.ac.uk
Competing interests

No financial interest/relationships with financial interest relating to the topic of this article have been declared by the authors.

Word Count: 2771 plus references
Total number of figures: 2
Total number of tables: 3
Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics ABT-199 and ABT-737.

Key words: AML, ABT-199, ABT-737, dormancy

Abstract
Cells from patients with acute myeloid leukaemia (AML) that remain dormant and protected by stromal cells may escape effects of chemotherapy. We modelled dormancy in vitro and investigated the ability of Bcl-2 inhibitors ABT-199 and ABT-737 to overcome chemoprotection of dormant cells. CD34-enriched primary AML cells with aberrant leukaemia-associated phenotypes (LAPs) were cultured on stromal cells. The chemosensitivity of dormant (PKH26\textsuperscript{high}), CD34+, LAP+ cells was ascertained by 5-colour flow cytometric counting after 12 days. The PKH26\textsuperscript{high}, CD34+, LAP+ subset retained clonogenic capacity. The dormant fraction was completely resistant to ara-C (P=0.007). However, ABT-199 and ABT-737 were able to reduce the dormant fraction by 84% and 80% respectively of their effects on proliferating counterparts. In conclusion, we have elaborated a system for quantifying chemosensitivity in LAP+ dormant leukaemia cells thought to contribute to disease relapse, and shown sensitivity of dormant LAP+ cells to ABT-199 and ABT-737 in this system.
Introduction

Relapse is common in patients with acute myeloid leukaemia after remission-induction with nucleoside analogue/anthracycline-based chemotherapy. The cells which give rise to relapse are likely to have evaded the effects of treatment by lying dormant [1, 2]. The concept of a dormant cancer cell can initially seem counter-intuitive, but in AML the presence of these cells has been substantiated by both functional and phenotypic evidence [1, 2, 3, 4, 5, 6, 7]. Dormant AML cells are concentrated adjacent to stromal cells [1, 8]. Protection of AML cells from chemotherapeutic drugs by proximity to stromal cells has been shown for several compounds, including the standard chemotherapeutics daunorubicin and cytarabine [1, 9, 10] as well as FLT3 inhibitors [5, 11]. Alvares and colleagues combined dormancy and niche in a single model and were able to demonstrate resistance to a FLT3 inhibitor in a dormant AML subpopulation cultured in vitro on stromal cells [5].

A potential novel approach to AML therapy is to target the B-cell lymphoma 2 (BCL2) protein family and thus directly induce apoptosis [12]. Anti-apoptotic members of the BCL2 family, i.e. BCL2, BCLXL, BCLW, BFL1 (A1), BCLB and MCL1, are considered as guardians of mitochondrial integrity by opposing pro-apoptotic BCL2 family proteins. In theory, oncogenic stresses may upregulate pro-apoptotic pathways, and therefore the successful cancer cell needs to have just enough functioning anti-apoptotic molecules to hold apoptosis in check. Cancer cells may therefore be dependent on (“addicted to”) survival gene expression and/or be “primed” by pro-apoptotic BH3 only proteins to readily undergo apoptosis once the anti-apoptotic family members are inhibited [13, 14, 15]. ABT-737 and ABT-199 (a reverse engineering version of ABT-737’s oral form ABT-263 that has high affinity for BCL-2 and lower affinity for BCLXL), have exhibited promising anti-cancer activities in vitro and in vivo [16, 17] including activity against AML cells [18, 19, 20, 21, 22]. Furthermore, these agents are found to significantly potentiate certain other
chemotherapeutics [22, 23, 24, 25, 26, 27, 28, 29], suggesting a promising future for novel drug combinations.

In the current study, we compare the sensitivities of proliferating and dormancy-enriched primary AML cells to ABT-199 and ABT-737. We show that aberrant phenotypes can persist through several days of culture on MS-5 stromal cells and we were able to use this finding in order to quantify dormant AML cells labelled with the proliferation marker PKH26 with and without the addition of ABT-199 and ABT-737.

**Materials and methods**

**Materials**

Antibodies were from BD Biosciences (Cowley, UK) and other reagents were from Sigma-Aldrich (Poole, UK), unless otherwise stated. TG02, originally designated SB1317, was kindly provided by Tragara Pharmaceuticals (Carlsbad, CA, USA). ABT-737 was from Sequoia Research products (Pangbourne, UK). ABT-199 was from Active BioChem (Hong-Kong). All three agents were reconstituted in Dimethyl sulfoxide (DMSO) and stored at 10 mM.

**AML Patient Samples**

Fresh or cryopreserved bone marrow or peripheral blood samples of patients presenting with *de novo* or relapsed AML were collected after written consent at diagnosis at the Nottingham University Hospitals. Use of these samples was approved by the Nottingham Research Ethics Committee and the samples were anonymised. Mononuclear cells were isolated using a standard density gradient/centrifugation method with Histopaque and red blood cells depleted from the sample using ammonium chloride. Cryopreserved samples kept in liquid nitrogen were thawed and rested in RPMI-1640 medium (Sigma-Aldrich, Poole, UK) enriched with
20% FCS (First Link, UK), for 60 to 90 minutes before experimental handling. Only samples with > 85% post-rest viability, assessed by trypan blue exclusion, were used. Leukaemia associated phenotypes (LAPs) were assessed by published methods [30] prior to culture.

**12-day Leukaemic cultures on stroma**

MS-5 stromal cells [31] were maintained at a density of 5 x 10^4/mL in α-minimum essential medium (α-MEM; Gibco, Paisley, UK), supplemented with 10% heat-inactivated FCS, 1% penicillin/streptomycin and 2mmol/L L-glutamine. For 12-day co-culture studies, MS-5 cells were sub-cultured at 2 x 10^4/mL on a gelatin-coated 12-well flat-bottom plate for 24 to 48 hours to form a monolayer before addition of AML cells. CD34^+ cells from fresh or cryopreserved AML samples were enriched by magnetic bead separation using Mini-MACS CD34 isolation kit (MiltenyiBiotec, Bisley, UK) and then labelled with the permanent cell membrane dye PKH26 according to manufacturers’ instructions. Labelled cells (at 2 x 10^6 cells/mL) were added to the MS-5 feeder layer and co-cultured in Gartner Medium [32]. Cells were kept in culture for 12 days and demi-populated on day 7. Drugs were added to cells on day 8 of the cell culture. On day 12, cells were harvested and processed for clonogenic assay and flow cytometric assessment as detailed below.

**Enumeration of viable, dormant LAP positive AML cells**

Immunophenotyping assays were performed on a FACS Canto II cytometer equipped with FACS-DIVA II software (Becton Dickinson, San Jose, USA). On days 0,7 and 12, cells were labelled with anti-CD45-APC.Cy7 and anti-CD34-APC clone BIRMA-K3 (Alere Ltd, Stockport, UK). Additional antibodies used to identify LAPs were anti-CD7- FITC (Beckman Coulter, Marseille, France) or anti-CD19-FITC. 7-AAD was used at 5μg/mL to exclude non-
viable cells. Dako CytoCount™ beads (Alere Ltd, Stockport, UK), were added as internal standard for cell counting.

*Methylcellulose Colony Formation (CFU) Assay*

Following 12-day culture, cells were labelled as above and sorted on a MoFlo™ XDP Cell Sorter (Beckman Coulter, Fullerton, CA, USA). Sorted cells were washed, re-suspended in StemSpan Expansion medium with 1% Stemspan CC100 cytokine cocktail for 3-4 days and transferred to Methocult H4034 colony medium (all from Stem Cell Technologies, Grenoble, France). Cells were plated onto 96-well flat-bottom plates at 2 \times 10^4 cells/100 µL in triplicates and were incubated at 37 °C in 5% CO₂ for 14 days. Colonies of >50 cells were counted.

*Statistics*

Data were analysed using SPSS 21 software package (Chicago, IL, USA).

*Results*

*Dormant primary leukaemia cells retaining clonogenic capacity can be identified after 12 days of co-culture and are effectively targeted by ABT-737 and ABT-199*

We established and validated a system for measuring the chemosensitivity of dormant primary leukaemia cells (Figure 1). After labelling CD34+ primary cells with PKH26 and culturing on MS-5 stromal cells for 12 days, we ascertained that the leukaemic nature of the cells following culture could be assured through the selection of samples with a major leukaemia associated phenotype (LAP). The aberrant CD34/CD7 and CD34/CD19 status of cells identified in presentation samples was maintained in the dormant subset throughout the 12 days of culture (Table I). We further ascertained the clonogenicity of sorted CD45
dimCD34+LAP+PKH26\textsuperscript{high} (dormant) subpopulation following the 12 day culture. We found that this subpopulation retained almost all of the clonogenic capacity compared to the CD45\textsuperscript{dim}CD34+/−LAP+PKH26\textsuperscript{low} cells that had already divided \textit{in vitro} (Table II). In two samples, a comparison of stromal support by MS-5 and by mesenchymal stem cells was made, with healthy human adult BM-MSCs cultured as described [33]. Clonogenicity of cells cultured by both methods was measured, but major differences were not observed (Table II).

Drugs were added after eight days to primary AML cells in the MS-5 co-culture system. The drug concentrations used were chosen on the basis that these were the average 72 hour IC\textsubscript{40} values determined in preliminary assays in suspension culture (data not shown). Chemosensitivity was ascertained by 5-colour flow cytometric counting using a suspension of CytoCount\textsuperscript{TM} fluorospheres as a reference population. Six samples were studied with this protocol as shown in Table III. We have previously shown that the multi-kinase inhibitor TG02, which targets transcriptional cyclin-dependent kinases, has efficacy against dormant AML cells [7] and we used this agent as a positive control. 200 nM Ara-C reduced the cell number by 49% in the cycling fraction, but there was no cell reduction at all in the dormant fraction (P=0.007, Figure 2). In contrast, exposure to ABT-199, ABT-737 and TG02 markedly reduced the number of both dormant and cycling cells. Although there is some favouring of cycled cells with these agents (Table III), we found that ABT-199 and ABT-737 were able to reduce the dormant cell fraction by 84% and 80% respectively of their effects in proliferating counterparts.

\textbf{Discussion}

The presence of dormant cells within a leukaemic clone presents the chemoresistance researcher with a distinct challenge, as most anti-neoplastic drugs have been designed to target proliferating cells as a surrogate for tumour cells, and therefore highly chemoresistant dormant cancer cells do not fit into the mainstream chemotherapeutic paradigm.
We built on a model previously described by Alvares and colleagues for identifying dormant cells grown on MS-5 stromal cells [5]. Additionally we used LAP markers to identify leukaemic cells against a background of potentially normal haematopoietic cells. We chose 12 days to approximate the length of time an AML cell would need to remain dormant to resist a course of chemotherapy. Guan and colleagues had demonstrated that the majority of *ex vivo* dormant AML cells rapidly re-enter the cell cycle *in vitro* [4], and thus phenotypic labelling of freshly isolated or thawed cells with dormancy markers might greatly overestimate the proportion of cells that would remain dormant, whereas the 12 day culture allowed us to be more confident that we were studying a clinically relevant subset of these cells. Our evaluation of this model indicated that not only could the expression of some LAP markers persist in the 12-day culture, but also that some dormant LAP
+ leukaemia cells maintained their clonogenic potential, thus alleviating our concern that the *in vitro* conditions may have rendered the cells senescent. A second argument against the *in vitro* induction of senescence in our model is that senescent cells are characterised by increased size and granularity and therefore have increased low-angle and orthogonal light scatter (forward scatter and side scatter) on flow cytometric analysis [34], whereas the CD34+/PKH
+ cells selected for analysis in our experiments retained low scatter properties – this is illustrated in the Figure 1 gating. The variability in proliferative abilities between cells within a single sample has been appreciated for several decades [35, 36], but the reasons why clonogenic cells can remain dormant in culture with stromal cells and then form colonies in semi-solid medium suggests a contribution from the stromal cells to the state of dormancy. The retention of clonogenic potential in PKH
+ but not PKH
- cells was very marked, and the use of LAP markers in the sorting process ensured that non-leukaemic cells were not affecting the output.

The efficacy of ABT-199 and ABT-737 in dormant cells cultured on MS-5 was at least 80% of their efficacy against cycled cells and the contrast to Ara-C, which completely failed to eradicate dormant primary cells when cultured on stromal cells, was pronounced. Primary samples differ enormously in their rates of cycling and therefore the proportion of cells likely to be vulnerable to ara-C [37]. Moreover, the osteoblastic niche has been shown to protect a dormant subset of AML cells from this drug [1]. The *in vitro* model system used thus enabled us to incorporate a protective stromal microenvironment, to discriminate between leukaemic and residual normal cells based on LAPs and
to contrast the effects of novel agents with the established drug araC which is selective for proliferating cells. The success of this model in assessing drug sensitivity in both cycling and dormant cell compartments, whilst unlikely to eliminate the need for *in vivo* models, has the potential to refine the number and scale of such studies.

2/6 samples used in this study were from patients with complex cytogenetics. A further patient with normal cytogenetics was studied with refractory disease. A fourth patient had transformed CMML and was unsuitable for intensive treatment. There were no good cytogenetic risk samples included. The high proportion of CD7+ aberrant phenotypes probably contributed to this bias. There have been at least 20 studies of aberrant CD7 expression in AML with very mixed results as to its prognostic value. However, the majority consensus appears to be that it is associated with normal or adverse cytogenetics and with multidrug resistance [38, 39]. This is therefore an interesting cohort to study with a view to identifying therapies from which hard-to-treat patients might benefit.

Evidence that BCL2 is therapeutically relevant in AML was established in our laboratory and by others nearly two decades ago [40, 41], but has been refined recently with the emergence of first ABT-737 and then ABT-199 as research tools and as drugs. An additional important discovery is that cells with low levels of reactive oxygen species (ROS-low), functionally defined as leukaemic stem cells, aberrantly over-express BCL-2 and are selectively targeted by ABT-737 [20]. ROS-low AML cells are enriched for dormant (Ki-67 negative) cells and therefore overlap the subpopulation we have investigated in the current work. An observation that AML cells with high BCL2 expression tend to have an impaired ability to enter the cell cycle has also been documented [42]. ABT-737 causes prolonged thrombocytopenia associated with BCLX\textsubscript{L} targeting, but ABT-199, which is more specific for Bcl-2, is of huge clinical interest: one report has been published [43] and 12 clinical studies are currently (September 2017) listed for ABT-199 (also known as venetoclax) in AML by clinicaltrials.gov. Our data suggest that this agent may have efficacy against cells protected by niche and dormancy. Analysis of post-treatment biopsies would be of great help to establish the cell cycle status of residual cells and thus whether venetoclax can eradicate dormant leukaemic cells in the clinic.
In summary, we have established and validated a system for the direct comparison of the chemosensitivity of intra-sample cycling and dormant leukemic cells. Using this methodology we have shown a differential response to araC in cycling versus dormant leukaemia cells, however ABT-199 and ABT-737 demonstrated effective targeting of both cellular compartments emphasising the potential importance of these agents in the clinical eradication of all leukaemic cells.

Acknowledgments

NY was supported by the Nottinghamshire Leukaemia Appeal.

Contributions

NY designed the study, developed methodology, performed and analysed experiments, and wrote the manuscript.

CS performed and analysed experiments and edited the manuscript.

NR designed the study, provided samples and demographics, and edited the manuscript.

MP designed the study, performed and supervised experiments, and wrote the manuscript.

FIGURE LEGENDS

Figure 1. 12 day culture of dormant primary AML cells

(A) Schema for dormant leukaemia cell chemosensitivity assay.

(B) and (C). Flow cytometric gating for dormant cells chemosensitivity assay. (B) On Day 0 the fluorescence of PKH-labelled CD34+ cells is recorded. (C) On day 12, (i) scatter, (ii) 7-AAD and (iii) CD45-gated plots combine to distinguish viable myeloid cells. (iv) LAP positive cells are identified (CD7 in this example). (v) Although most cells have decreased/lost PKH-26 and/or CD34 compared with Day 0, a sub-population of non-dividing (PKH26$^{high}$) cells is detected in CD34+, LAP+ myeloid blasts.

Figure 2. Sensitivity to ABT-199 and ABT-737 in 12 day culture of dormant primary AML cells
The bar chart shows percentage surviving cells compared with untreated controls in the dormant and cycled fractions of AML blasts after 12 days culture on MS-5 stromal cells (n=5, mean + standard deviation). 100 nM ABT-199, 100 nM ABT-737, 25 nM TG02 or 200 nM Ara-C were added on Day 8.

References

1. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature biotechnology. 2007 Nov;25(11):1315-21. PubMed PMID: 17952057.
2. Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nature biotechnology. 2010;28(3):275-80. doi: nbt.1607 [pii]10.1038/nbt.1607. PubMed PMID: 20160717.
3. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004 Jul;5(7):738-43. PubMed PMID: 15170211.
4. Guan Y, Gerhard B, Hogge DE. Detection, Isolation and Stimulation of Quiescent Primitive Leukemic Progenitor Cells from Patients with Acute Myeloid Leukemia (AML). Blood. 2003;101:3142-3149.
5. Alvares CL, Schenk T, Hulki S, et al. Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutations. British journal of haematology. 2011 Aug;154(4):457-65. doi: 10.1111/j.1365-2411.2011.08748.x. PubMed PMID: 21689085.
6. Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia. 1990;4(12):826-34.
7. Pallis M, Burrows F, Whittall A, et al. Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC pharmacology & toxicology. 2013 Jun 15;14(1):32. doi: 10.1186/2050-6511-14-32. PubMed PMID: 23767415; PubMed Central PMCID: PMC3685571.
8. Tabe Y, Shi YX, Zeng Z, et al. TGF-beta-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One. 2013;8(6):e62785. doi: 10.1371/journal.pone.0062785. PubMed PMID: 23826077; PubMed Central PMCID: PMC3695026.
9. Garrido SM, Appelbaum FR, Willman CL, et al. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Experimental hematology. 2001 Apr;29(4):448-57. PubMed PMID: 11301185.
10. Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002 Sep;16(9):1713-24. doi: 10.1038/sj.leu.2402608. PubMed PMID: 12200686.
11. Zeng Z, Shi YX, Samudio JJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009 Jun 11;113(24):6215-24. doi: blood-2008-05-158311 [pii]10.1182/blood-2008-05-158311. PubMed PMID: 18955566.
12. Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature reviews Molecular cell biology. 2014 Jan;15(1):49-63. doi: 10.1038/nrm3722. PubMed PMID: 24355989.

13. Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Molecular and cellular biology. 1997 Dec;17(12):7306-16. PubMed PMID: 9372962.

14. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006 May;9(5):351-65. doi: S1535-6108(06)00113-9 [pii]10.1016/j.ccr.2006.03.027. PubMed PMID: 16697956.

15. Del Gaizo Moore V, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. The Journal of clinical investigation. 2007 Jan;117(1):112-21. doi: 10.1172/JCI28281. PubMed PMID: 17200714; PubMed Central PMCID: PMC1716201.

16. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005 Jun 2;435(7042):677-81. doi: nature03579 [pii]10.1038/nature03579. PubMed PMID: 15902208.

17. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Jan 6;19(2):202-208. doi: 10.1038/nm.3048. PubMed PMID: 2321630.

18. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov;10(5):375-88. doi: S1535-6108(06)00313-8 [pii]10.1016/j.ccr.2006.10.006. PubMed PMID: 17097560.

19. Vo TT, Ryan J, Carrasco R, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012 Oct 12;151(2):344-55. doi: 10.1016/j.cell.2012.08.038. PubMed PMID: 23063124; PubMed Central PMCID: PMC3975047.

20. Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013 Mar 7;12(3):329-41. doi: 10.1016/j.stem.2012.12.013. PubMed PMID: 23333149; PubMed Central PMCID: PMC3595363.

21. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer discovery. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. PubMed PMID: 24346116; PubMed Central PMCID: PMC3975047.

22. Pallis M, Burrows F, Ryan J, et al. Complementary dynamic BH3 profiles predict cooperativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget. 2017 Mar 07;8(10):16220-16232. doi: 10.18632/oncotarget.8742. PubMed PMID: 27092880; PubMed Central PMCID: PMC5369958.

23. Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014 Jan 23. doi: 10.1038/leu.2014.44. PubMed PMID: 24451410.

24. Chen S, Dai Y, Harada H, et al. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007 Jan 15;67(2):782-91. doi: 67/2/782 [pii]10.1158/0008-5472.CAN-06-3964. PubMed PMID: 17234790.

25. Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Molecular cancer therapeutics. 2011 Dec;10(12):2340-9. doi: 10.1158/1535-7163.MCT-11-0415. PubMed PMID: 21914853.

26. Kohl TM, Hellinger C, Ahmed F, et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia. 2007 Aug;21(8):1763-72. doi: 2404776 [pii]10.1038/sj.leu.2404776. PubMed PMID: 17554384.
27. Konopleva M, Milella M, Ruvolo P, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. 2012 Apr;26(4):778-87. doi: 10.1038/leu.2011.287. PubMed PMID: 22064351; PubMed Central PMCID: PMC3604791.

28. Iacovelli S, Ricciardi MR, Allegretti M, et al. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BHM mimetics resistant acute lymphoblastic leukemia. Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156. PubMed PMID: 26392332; PubMed Central PMCID: PMC4741661.

29. Larrayoz M, Blakemore SJ, Dobson RC, et al. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia. 2016 Feb;30(2):351-60. doi: 10.1038/leu.2015.286. PubMed PMID: 26488112.

30. Feller N, van der Velden VH, Brooimans RA, et al. Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood cancer journal. 2013;3:e129. doi: 10.1038/bcj.2013.27. PubMed PMID: 23912609; PubMed Central PMCID: PMC3763381.

31. Issaad C, Croisille L, Katz A, et al. A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38- progenitor cells in long-term cultures and semisolid assays. Blood. 1993 Jun 1;81(11):2916-24. PubMed PMID: 7684620.

32. Gartner S, Kaplan HS. Long-term culture of human bone marrow cells. Proc Natl Acad Sci U S A. 1980 Aug;77(8):4756-9. PubMed PMID: 6933522; PubMed Central PMCID: PMC349925.

33. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002 Jul 1;62(13):3603-8. PubMed PMID: 12097260.

34. Hwang ES, Yoon G, Kang HT. A comparative analysis of the cell biology of senescence and aging. Cellular and molecular life sciences : CMLS. 2009 Aug;66(15):2503-24. doi: 10.1007/s00018-009-0034-2. PubMed PMID: 19421842.

35. Buick R, Minden M, McCulloch EA. Self-renewal in culture of proliferative blast cell progenitor cells in acute myeloblastic leukemia. Blood. 1979;54:65-95.

36. Sutherland H, Blair A, Vercauteren S, et al. Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long-term proliferation in vitro. British journal of haematology. 2001 Aug;114(2):296-306. PubMed PMID: 11529847.

37. Raza A, Maheshwari Y, Preisler HD. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood. 1987 Jun;69(6):1647-53. PubMed PMID: 3555651.

38. Kornblau SM, Thall P, Huh YO, et al. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia. 1995 Oct;9(10):1735-41. PubMed PMID: 7564518.

39. Del Poeta G, Stasi R, Venditti A, et al. CD7 expression in acute myeloid leukemia. Leukemia & lymphoma. 1995 Mar;17(1-2):111-9. doi: 10.3109/10428199509051710. PubMed PMID: 7539657.

40. Keith FJ, Bradbury DA, Zhu Y-M, et al. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia. 1995;9:131-138.

41. Konopleva M, Tari AM, Estrov Z, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensititize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000;95(12):3929-38.

42. Konopleva M, Zhao S, Hu W, et al. The anti-apoptotic genes Bcl-XL and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. British journal of haematology. 2002;118(2):521-34.

43. Konopleva M, Polleyea DA, Potluri J, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer discovery. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.cd-16-0313. PubMed PMID: 27520294; PubMed Central PMCID: PMCPMC5436271.
Table I. Retention of aberrant surface marker (LAP) expression after 12-day culture of primary AML cells

| AML sample | Days in culture | LAP marker | LAP cells as % of total AML cells | LAP cells in the CD45<sup>dim</sup>CD34<sup>+</sup>PKH26<sup>high</sup> compartment (%) |
|------------|----------------|------------|-----------------------------------|--------------------------------------------------|
| 603        | Day 0          | CD7        | 85.5                              | 79.1                                             |
|            | Day 7          |            | 68.1                              | 77.4                                             |
|            | Day 12         |            | 13.8                              | 77.2                                             |
| 596        | Day 0          | CD7        | 84.6                              | 89.1                                             |
|            | Day 7          |            | 73.6                              | 83.4                                             |
|            | Day 12         |            | 12.5                              | 83.9                                             |
| 582        | Day 0          | CD19       | 43.1                              | 54.7                                             |
|            | Day 7          |            | 38.5                              | 44.8                                             |
|            | Day 12         |            | 37.3                              | 41.3                                             |
| 536        | Day 0          | CD7        | 61.3                              | 85.1                                             |
|            | Day 7          |            | 55.4                              | 84.3                                             |
|            | Day 12         |            | 53.9                              | 80.4                                             |
| 444        | Day 0          | CD7        | 86.4                              | 98.4                                             |
|            | Day 7          |            | 73.1                              | 87.2                                             |
|            | Day 12         |            | 41.4                              | 86.9                                             |
| 601        | Day 0          | CD7        | 32.9                              | 92.1                                             |
|            | Day 12         |            | 26.3                              | 72.9                                             |
Table II. Colony frequency in sorted fractions from de novo AML samples after 12-day culture

| AML sample | Subset      | Total sorted cells | Total colony count | Standardised colony growth rate (per 10,000 cells) |
|------------|-------------|--------------------|--------------------|--------------------------------------------------|
| 603        | dormant     | 1471               | 11                 | 75                                               |
|            | cycled      | 344                | 0                  | 0                                                |
| 596        | dormant     | 717                | 17                 | 237                                              |
|            | cycled      | 8510               | 2                  | 2                                                |
| 582        | dormant     | 6530               | 31                 | 47                                               |
|            | cycled      | 9830               | 3                  | 3                                                |
| 536        | dormant     | 10390              | 55                 | 53                                               |
|            | cycled      | 230750             | 3                  | 1                                                |
| 444        | dormant     | 6306               | 54                 | 86                                               |
|            | cycled      | 10757              | 0                  | 0                                                |
| 603 MSC*   | dormant     | 1070               | 4                  | 37                                               |
|            | cycling     | 128                | 0                  | 0                                                |
| 596 MSC*   | dormant     | 352                | 15                 | 426                                              |
|            | cycling     | 3359               | 1                  | 3                                                |

*Although MS-5 cells were used in all cases, in two cases (#603 and #596) we also used primary mesenchymal stem cells (MSC) so that the clonogenic yield from each support system could be compared.
Table III. Samples studied in 12-day culture

| Demographics               | Sample | 603 | 582 | 596 | 444 | 536 | 601 |
|----------------------------|--------|-----|-----|-----|-----|-----|-----|
| **patient age**            |        | 64  | 42  | 67  | 71  | 40  | 61  |
| LAP                        |        | CD34| CD34| CD34| CD34| CD34| CD34|
| LAP                        | CD7    | CD7 | CD7 | CD7 | CD7 | CD7 | CD7 |
| **NPM1 status**            |        | wildtype | wildtype | mutant | wildtype | wildtype | wildtype |
| **FLT3 ITD status**        |        | wildtype | mutant | mutant | wildtype | wildtype | mutant |
| **FLT3 point mutation status** |   | wildtype | wildtype | wildtype | wildtype | wildtype | wildtype |
| **Cytogenetics**           |        | complex | MLL, +11 | 46XX del(2)(q11q21) | normal | complex | normal |
| **%CD34**                  |        | 76  | 76  | 10  | 91  | 16  | 10.5|
| **%CD34+ CD38-**           |        | 0.2 | 0.031 | 2.407 | not done | 0.04 | 2.1 |
| **category**               |        | de novo | de novo | de novo | refractor y | relapse after transplant | transformed CMML |
| araC                       |        |      |      |      |      |      |      |
| **cycled**                 |        | 52  | 51  | 62  | 97  | 48  | n/a*|
| **dormant**                |        | 104 | 117 | 105 | 111 | 97  | 100 |
| ABT-737                    |        |      |      |      |      |      |      |
| **cycled**                 |        | 43  | 8   | 31  | 39  | 37  | n/a*|
| **dormant**                |        | 49  | 39  | 46  | 32  | 60  | 61  |
| ABT-199                    |        |      |      |      |      |      |      |
| **cycled**                 |        | 39  | 30  | 29  | 7   | 32  | n/a*|
| **dormant**                |        | 47  | 36  | 40  | 14  | 60  | 42  |
| TG02                       |        |      |      |      |      |      |      |
| **cycled**                 |        | 48  | 17  | 40  | 59  | 42  | n/a*|
| **dormant**                |        | 65  | 41  | 62  | 47  | 81  | 73  |

* This sample lacked a cycled subset after 12 days. (It was therefore excluded from the comparative graph)
**Figure 1**

A) **Day 0**
- CD34 enrich primary AML blasts
- Label with PKH26

I) Co-culture on stroma (MS-5)

Day 7
- Change half the medium

Day 8
- Add drugs

Day 12
- Cell harvest.
  - Label cells with CD45, CD34, 7AAD, LAP marker
  - Analyse and count (with CytoCount™)

Sort
- CD45+, LAP+, 7AADlow,
  - CD34+, PKH26high and
  - CD45+, LAP+, 7AADlow
  - CD34 +/-PKH26low

Validate with colony assay

B) **Day 0**
- PKH26
- CD34

C) **Day 12**

i) Viability cells (7-AAD™)

ii) Leukemic cells (CD7/LAP™)

iii) Hematopoietic (CD45+™)

iv) Leukemic cells (CD7/LAP™)

v) Derived fraction (PKH26™)

- CD34

CD34
Table III. Samples studied in 12-day culture

| Demographics       | Sample  | 603 | 582 | 596 | 444 | 536 | 601 |
|--------------------|---------|-----|-----|-----|-----|-----|-----|
| patient age        |         | 64  | 42  | 67  | 71  | 40  | 61  |
| LAP                |         | CD34| CD34| CD34| CD34| CD34| CD34|
| CD7                |         | CD34| CD19| CD7 | CD7 | CD7 | CD7 |
| NPM1 status        |         | wildtype| wildtype| mutant| wildtype| wildtype| wildtype|
| FLT3 ITD status    |         | wildtype| mutant| mutant| wildtype| wildtype| mutant|
| FLT3 point mutation status | | wildtype| wildtype| wildtype| wildtype| wildtype| wildtype|
| Cytogenetics       |         | complex| MLL, +11| 46XX| del(2)(q11q21)| der(7)t(1;7)(q22), add(11)(q2)| normal| complex| normal|
| %CD34+             |         | 76  | 76  | 10  | 91  | 16  | 10.5|
| %CD34+ CD38-       |         | 0.2 | 0.031| 2.407| not done| 0.04| 2.1 |
| category           |         | de novo| de novo| de novo| refractor y| relapse after transplant| transformed CMML|
| araC               |         |    |    |    |    |    |    |
| cycled             |         | 52 | 51 | 62 | 97 | 48 | n/a*|
| dormant            |         | 104| 117| 105| 111| 97 | 100|
| ABT-737            |         |    |    |    |    |    |    |
| cycled             |         | 43 | 8  | 31 | 39 | 37 | n/a*|
| dormant            |         | 49 | 39 | 46 | 32 | 60 | 61 |
| ABT-199            |         |    |    |    |    |    |    |
| cycled             |         | 39 | 30 | 29 | 7  | 32 | n/a*|
| dormant            |         | 47 | 36 | 40 | 14 | 60 | 42 |
| TG02               |         |    |    |    |    |    |    |
| cycled             |         | 48 | 17 | 40 | 59 | 42 | n/a*|
| dormant            |         | 65 | 41 | 62 | 47 | 81 | 73 |

* This sample lacked a cycled subset after 12 days. (It was therefore excluded from the comparative graph)
